BIO.NYSEBio-rad Laboratories, INC
DEF: Bio-Rad Seeks Shareholder Approval Amid Performance Concerns
Sentiment:
Proxy Statement for Annual Meeting
Bio-Rad Laboratories, Inc. issues its 2026 proxy statement, seeking approval for director elections, auditor ratification, executive compensation, and an expanded equity incentive plan, while facing a shareholder proposal to eliminate its dual-class stock structure.
Worse than expectedThe company's Total Shareholder Return (TSR) of $51.98 (from an initial $100 investment in 2021) is significantly worse than the Peer Group TSR of $105.15 over the same period.Operating income for 2025 was $47,111,410, which is substantially lower than the 2025 IBP Target Plan Adjusted Operating Income of $353.5 million, and also significantly lower than operating income in prior years (e.g., $500.3 million in 2021).The CEO's bonus under the 2025 IBP was 41.25% of his target opportunity, indicating a significant underachievement against his specific performance metrics.
Summary
- The annual meeting will be held on April 21, 2026, to vote on the election of six directors, ratification of KPMG LLP as independent auditors, an advisory vote on executive compensation, and the approval of the Amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan.
- A shareholder proposal requests the Board to take steps to enable all outstanding stock to have an equal one-vote per share, challenging the current dual-class structure where Class B shares (primarily held by the Schwartz family) have significantly more voting power.
- The Board recommends against the dual-class structure proposal, arguing it supports the company's long-term vision and management continuity.
- The Amended 2017 Incentive Award Plan seeks to increase the shares reserved for issuance by 335,000 and extend its expiration date to March 18, 2036.
- Executive compensation for 2025 includes significant stock and option awards, with CEO Norman Schwartz receiving a total of $7,995,841.
- The company's 2025 Incentive Bonus Plan (IBP) achieved 97.1% of its Global Sales target and 92.5% of its Operating Income target, resulting in bonuses for most named executive officers (NEOs) at 70.8% of target, while the CEO received 41.25% of his target bonus due to specific adjustments.
- Net income for 2025 was $759,913,156, a significant recovery from losses in prior years, but operating income remained low at $47,111,410.
- The CEO to median employee pay ratio for 2025 was 97:1, with the median employee's total compensation at $82,784.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this filing with caution due to significant underperformance in Total Shareholder Return compared to peers, persistently low operating income, and the ongoing corporate governance debate surrounding the dual-class share structure, despite a rebound in net income.
Positives
- Net income for 2025 significantly rebounded to $759,913,156 from substantial losses in 2024 and 2023.
- The company is actively making significant management changes, bringing in new executive talent across key operational and financial roles, including new Presidents for Life Science and Clinical Diagnostics Groups, a new CFO, and a new General Counsel.
- The Board has adopted robust corporate governance policies, including equity ownership guidelines for directors and senior executives, and a clawback policy for incentive-based compensation.
- The company achieved 97.1% of its Global Sales target and 92.5% of its Operating Income target under the 2025 Incentive Bonus Plan, indicating solid performance against internal metrics.
- KPMG LLP was selected as independent auditors for the fiscal year ending December 31, 2026, indicating continuity in audit oversight.
Negatives
- The company's Total Shareholder Return (TSR) has significantly underperformed its peer group over the past five years, with a $100 investment in 2021 yielding $51.98 by 2025, compared to the peer group's $105.15.
- Operating income for 2025 was low at $47,111,410, a substantial decrease from previous years ($269 million in 2024, $337.8 million in 2023, $482.6 million in 2022, $500.3 million in 2021).
- The dual-class capital structure, where the Schwartz family controls over 50% of voting power with Class B shares, is a point of contention and is subject to a shareholder proposal for elimination, raising corporate governance concerns regarding equal voting rights.
- Executive compensation, particularly for the CEO, remains high despite the company's poor TSR and declining operating income in recent years.
- The request to increase shares for the incentive plan by 335,000 and extend its term could be viewed negatively by some investors due to potential dilution concerns, especially given recent stock performance.
Risks
- The dual-class capital structure concentrates voting power with the Schwartz family, potentially limiting the influence of other shareholders on corporate governance and strategic decisions.
- Failure to achieve performance goals under the Incentive Bonus Plan could impact employee motivation and retention, affecting future operational results.
- The company's historical burn rate of 0.97% (3-year average) and expected overhang of 4.31% (if the Amended Equity Plan is approved) indicate potential for future share dilution, which could negatively impact shareholder value.
- The company's stock price experienced a significant decline from $832 in 2021 to $297 in late 2025, indicating market volatility and potential investor dissatisfaction, which could persist.
- The company faces risks related to compliance with the Foreign Corrupt Practices Act, anti-corruption, anti-kickback, false-claims laws, and cybersecurity, requiring robust oversight by the Legal and Regulatory Compliance Committee.
Future Outlook
The company estimates that the shares reserved for issuance under the Amended Equity Plan, if approved, would be sufficient for approximately 2-3 years of awards, assuming historical usage rates. The Board's opposition to the dual-class structure proposal emphasizes a focus on long-term success, sustained investment, and continuity of management. The next say-on-pay advisory vote is expected at the 2029 annual meeting.
Management Comments
- "Our Board believes that our current capital structure is in the best interest of our company and its stockholders."
- "Our current capital structure allows our Board and management team to focus on the long term."
- "Our business requires sustained investment, consistent execution of our strategy, and the willingness to pursue initiatives whose value may not be immediately reflected in near-term financial results."
- "Our Board provides effective independent oversight and ensures that the interests of all of our stockholders are considered."
Industry Context
StockSavvy.ai notes that Bio-Rad operates in the competitive life sciences and medical products sectors, as evidenced by its peer group selection including companies like Agilent Technologies, Illumina, and Thermo Fisher Scientific. The significant management changes, including new Presidents for Life Science and Clinical Diagnostics Groups, and new CFO and General Counsel, suggest a strategic effort to enhance operational efficiency and market positioning in a dynamic industry. The company's underperformance in TSR compared to its peer group highlights the intense competition and the need for effective strategic execution to capture market share and deliver shareholder value.
Comparison to Industry Standards
- Bio-Rad's Total Shareholder Return (TSR) of $51.98 (from an initial $100 investment in 2021) significantly underperformed the S&P 500 Life Sciences Tools & Services Index, which yielded $105.15 over the same period, indicating a substantial lag behind industry benchmarks.
- The CEO to median employee pay ratio of 97:1 is within the range observed in the broader S&P 500, but the high executive compensation, particularly the CEO's $7.99 million total compensation in 2025, stands out given the company's recent negative net income and declining operating income in prior years, and the underperforming TSR relative to peers.
- The company's dual-class share structure, while defended by the Board for long-term focus, contrasts with the single-class structure favored by many institutional investors and corporate governance advocates, such as the Council of Institutional Investors (CII) and the International Corporate Governance Network (ICGN), who recommend time-based sunset clauses for such structures. Companies like Meta, Visa, Ford, Alphabet, and Berkshire Hathaway are cited by the Board as examples of successful dual-class structures, but these often have different growth trajectories and market perceptions.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Executive Vice President, President, Life Science Group | NA | James Barry | May 2024 | Appointment to new role. |
| President and Chief Operating Officer | NA | Jonathan P. DiVincenzo | September 2024 | Appointment to new role. |
| Executive Vice President, President, Clinical Diagnostics Group | NA | Eva Anette Engelhardt | June 2024 | Appointment to new role. |
| Executive Vice President, General Counsel and Secretary | NA | Courtney C. Enloe | April 2024 | Appointment to new role. |
| Executive Vice President, Global Supply Chain | NA | Sedat Evran | September 2023 | Appointment to new role. |
| Executive Vice President, Chief Financial Officer | NA | Roop K. Lakkaraju | April 2024 | Appointment to new role. |
| Executive Vice President, Global Commercial Operations | NA | Rajat Mehta | August 2025 | Appointment to new role. |
| Vice President, Global Supply Chain Clinical Diagnostics Group Operations | Commercial Director at Bio-Rad Laboratories (Canada) Limited | Allison Schwartz | November 2024 | Promotion within the company. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation Policy | Board approved a compensation policy for non-employee directors, effective October 1, 2023, providing specific cash fees for various roles and an annual equity grant of $100,000 in Class A Common Stock restricted stock units. | 2023-10-01 | Standardizes and formalizes non-employee director compensation, aligning with market practices. |
| Equity Ownership Guidelines for Non-Employee Directors | Company adopted guidelines requiring non-employee directors to hold shares of common stock equal in value to at least $400,000 within five years from adoption or initial grant date. | 2024-10-24 | Enhances alignment of non-employee directors' long-term financial interests with stockholders. |
| Executive Stock Ownership Guidelines | Company adopted stock ownership guidelines for senior executives (EVP level and above), requiring the CEO to hold shares equal to five times salary and other EVPs two times salary, within five years. | 2022-06-01 | Strengthens alignment of executive long-term financial interests with stockholders. |
| Clawback Policy | Company adopted a clawback policy in compliance with NYSE listing standards and Section 10D of the Exchange Act, requiring recoupment of erroneously awarded incentive-based compensation from Section 16 officers. | 2023-10-02 | Enhances corporate accountability and compliance with regulatory requirements. |
| Amended 2017 Incentive Award Plan | Proposed amendments include increasing shares reserved for issuance by 335,000 and extending the plan's expiration date to March 18, 2036. New features include a one-year minimum vesting period for awards (with limited exceptions), a clawback policy, prohibition on dividend equivalents on unvested awards, and prohibition on repricing options/SARs without stockholder approval. | 2026-03-18 | Aims to provide continued incentives for employees and directors, but the share increase could lead to dilution. The new features align with evolving governance best practices. |
Related Party Transactions
- Allison Schwartz, daughter of CEO Norman Schwartz and a director, received $354,239 in base salary and bonus, plus $146,424 in expatriate benefits (tax equalization and tax preparation fees) in 2025, in connection with her employment as Vice President, Global Supply Chain Clinical Diagnostics Group Operations.
Stakeholder Impact
- Shareholders: Potential for dilution from the proposed increase in the equity incentive plan. The dual-class structure continues to limit the voting power of Class A shareholders, which is a point of contention. Underperformance in TSR compared to peers may concern investors.
- Employees: The expanded equity incentive plan provides continued opportunities for stock-based compensation, which can aid in attraction and retention. The Incentive Bonus Plan links bonuses to company performance.
- Management: New executive appointments indicate a refreshed leadership team. Executive compensation remains competitive, but performance-based bonuses are tied to company metrics.
- Customers/Suppliers: No direct impact mentioned, but the focus on long-term strategy and innovation could indirectly benefit customers through product development.
- Creditors: No direct impact mentioned.
Next Steps
- Stockholders will vote on director elections, auditor ratification, executive compensation, and the Amended 2017 Incentive Award Plan at the Annual Meeting on April 21, 2026.
- Stockholders will vote on a proposal regarding the dual-class capital structure at the Annual Meeting on April 21, 2026.
- The company will continue to consider the outcome of say-on-pay votes in future compensation decisions.
- The next say-on-pay advisory vote is scheduled for the 2029 annual meeting of stockholders.
- Stockholders wishing to include a proposal in the 2027 proxy statement must submit it by November 25, 2026.
Key Dates
| Date | Description |
|---|---|
| 1983-01-01 | Gregory K. Hinckley served as Chief Financial Officer for Bio-Rad. |
| 1989-01-01 | Gregory K. Hinckley concluded his role as Chief Financial Officer for Bio-Rad. |
| 1992-01-01 | Audit Committee was established. |
| 1995-01-01 | Norman Schwartz became a Director. |
| 2000-06-07 | Board of Directors adopted an Audit Committee Charter. |
| 2003-01-01 | Norman Schwartz became Chief Executive Officer. |
| 2005-01-01 | Allison Schwartz joined Bio-Rad. |
| 2012-01-01 | Norman Schwartz became Chairman of the Board. |
| 2013-07-24 | Board of Directors adopted a Compensation Committee charter. |
| 2017-02-15 | Board first approved the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan (2017 Effective Date). |
| 2017-04-25 | Stockholders approved the 2017 Incentive Award Plan. |
| 2017-04-26 | Legal and Regulatory Compliance Committee was formed. |
| 2017-09-05 | Grant date for Norman Schwartz's 13,000 stock options. |
| 2018-02-21 | Audit Committee Charter was most recently amended. |
| 2018-09-04 | Grant date for Norman Schwartz's 13,000 stock options. |
| 2019-09-03 | Grant date for Norman Schwartz's 11,597 stock options. |
| 2020-09-02 | Grant date for Norman Schwartz's 7,220 stock options. |
| 2021-09-01 | Grant date for Norman Schwartz's 5,064 stock options and James Barry's RSUs. |
| 2022-01-01 | Allison Schwartz became a Director. |
| 2022-02-01 | Board of directors adopted an Executive Change in Control Severance Plan. |
| 2022-09-01 | Grant date for Norman Schwartz's RSUs. |
| 2023-01-01 | Measuring period for median employee compensation began. |
| 2023-09-01 | Grant date for Norman Schwartz's RSUs and James Barry's RSUs. |
| 2023-09-30 | Measuring period for median employee compensation ended. |
| 2023-10-01 | Effective date for non-employee director compensation policy and date for establishing employee population for median employee identification. |
| 2023-10-02 | Company adopted a clawback policy in compliance with NYSE listing standards and Section 10D of the Exchange Act. |
| 2023-10-20 | Legal and Regulatory Compliance Committee charter was most recently amended. |
| 2023-12-18 | Compensation Committee charter was most recently amended. |
| 2023-12-31 | Exchange rates used for foreign currency compensation conversion for median employee identification. |
| 2024-02-09 | The 2017 Incentive Award Plan was subsequently amended by the Board. |
| 2024-03-08 | Grant date for Norman Schwartz's and James Barry's stock options. |
| 2024-04-23 | Stockholders approved the amended 2017 Incentive Award Plan. |
| 2024-04-24 | Roop K. Lakkaraju's RSUs grant date. |
| 2024-05-01 | James Barry was appointed Executive Vice President, President, Life Science Group. |
| 2024-09-01 | Jonathan P. DiVincenzo was appointed President and Chief Operating Officer. |
| 2024-09-05 | Grant date for Norman Schwartz's RSUs and Roop K. Lakkaraju's RSUs. |
| 2024-09-06 | Board meeting where annual RSU grants to non-employee directors were approved to occur automatically on the date of the annual stockholder meeting starting in 2025. |
| 2024-10-24 | Jonathan P. DiVincenzo's RSUs grant date. |
| 2024-10-24 | Company adopted non-employee director equity ownership guidelines. |
| 2024-11-01 | Allison Schwartz was appointed Vice President, Global Supply Chain Clinical Diagnostics Group Operations. |
| 2024-12-31 | Fiscal year end for 2024 financial data. |
| 2025-02-07 | Board of Directors approved 2025 option grants to named executive officers. |
| 2025-02-15 | Sign-on bonus of $1,300,000 paid to Mr. DiVincenzo. |
| 2025-03-03 | Grant date for 2025 non-qualified stock options for named executive officers. |
| 2025-04-01 | Effective date for merit increases to named executive officers' base pay. |
| 2025-04-22 | Grant date for 407 RSUs to each non-employee director. |
| 2025-07-01 | Arnold A. Pinkston retired from Edwards Lifesciences Corporation. |
| 2025-08-01 | Rajat Mehta was appointed Executive Vice President, Global Commercial Operations. |
| 2025-09-05 | Board of Directors approved 2025 RSU grants to named executive officers. |
| 2025-12-31 | Fiscal year end for 2025 financial data and equity compensation plan information. |
| 2026-02-23 | Record date for stockholders entitled to notice of and to vote at the annual meeting. |
| 2026-03-18 | Proposed new expiration date for the Amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan. |
| 2026-03-25 | Proxy statement and accompanying proxy card(s) first distributed to stockholders of record. |
| 2026-04-21 | Annual Meeting of Stockholders. |
| 2026-11-25 | Deadline for stockholders to deliver proposals for inclusion in next year's proxy statement. |
| 2026-12-22 | Earliest date for stockholder notice of business proposals or director nominations for 2027 annual meeting. |
| 2027-01-21 | Latest date for stockholder notice of business proposals or director nominations for 2027 annual meeting. |
| 2027-12-31 | Estimated year by which the share limit under the Existing Equity Plan would be exhausted if not increased. |
| 2029-01-01 | Next say-on-pay advisory vote expected to be held at the 2029 annual meeting of stockholders. |
Recommendation
holdBio-Rad Laboratories presents a mixed picture. While the company reported a significant rebound in net income for 2025 and is actively refreshing its management team, its Total Shareholder Return has substantially underperformed its peer group over the past five years, and operating income remains low. The dual-class share structure continues to be a corporate governance concern, limiting the influence of many shareholders. The proposed expansion of the equity incentive plan, while necessary for talent retention, adds to potential dilution. Given the recent underperformance but also the strategic management changes and net income recovery, a "hold" recommendation is appropriate, suggesting investors monitor the effectiveness of the new leadership and the impact of the governance structure on long-term value creation.
Keywords
Bio-Rad Laboratories, SEC Filing, Proxy Statement, Corporate Governance, Executive Compensation, Dual-Class Stock, Incentive Award Plan, Shareholder Meeting, Director Election, Auditor Ratification, Financial Performance, Stockholder Proposal, Equity Compensation, Risk Management, Life Sciences, Clinical Diagnostics, Biopharmaceutical, Medical Devices
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.